Duration of symptom

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months

After cessation of oral medications at 6 months, significantly fewer women in the anticholinergic group maintained adequate symptom control at month 7 compared to onabotulinumtoxinA (50% vs 62%, P=0.0

Effect: improvement; 62% vs 50% adequate control at 7 months; 38% vs 25% at 12 months